Journal of Clinical Oncology

First-Line Procarbazine, CCNU, and Vincristine With Radiotherapy in IDH-Mutant Oligodendroglioma – Journal of Clinical Oncology

Journal of Clinical Oncology shared a post on X:

“Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.”

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

Authors: Salah Eddine O. Kacimi, et al.

 

First-Line Procarbazine, CCNU, and Vincristine With Radiotherapy in IDH-Mutant Oligodendroglioma - Journal of Clinical Oncology

cancer cancer awareness cancer care CCNU fight against cancer Global fight against cancer JCO Journal of Clinical Oncology Oligodendroglioma OncoDaily Oncology Procarbazine radiotherapy Salah Eddine O. Kacimi